利用临床急诊科数据集估算加拿大两剂COVID-19疫苗有效性与保护持续时间
研究利用加拿大COVID-19急诊科快速响应网络10个站点的前瞻性急诊数据,采用检测阴性设计估算两剂mRNA疫苗对SARS-CoV-2相关急诊就诊的疫苗有效性(VE)。在3405例符合条件患者中,接种后7-55天调整VE为93.3%(95%CI 87.9-96.3%),至接种后139天仍维持80%以上,且在部分免疫受损、慢性肾病、肺病、住房不稳定及非法药物使用亚组中VE相似。
要点
- 两剂mRNA疫苗对SARS-CoV-2相关急诊就诊的调整VE为93.3%(95%CI 87.9-96.3%),接种后7-55天。
- VE在接种后139天内维持80%以上。
- 在免疫受损、慢性肾病、肺病、住房不稳定及非法药物使用亚组中VE相似。
核心结论
- 两剂mRNA疫苗对SARS-CoV-2相关急诊就诊的VE高且持久,包括在脆弱亚组中。
- 与行政数据集相比,主动急诊入组能够标准化检测可及性和指征,并支持在特殊人群亚组中单独评估VE。
- 与其他主动入组环境相比,当替代医疗部门不同程度关闭时,急诊科在危机期间更持续地运作。
研究设计与样本
- 采用检测阴性设计,数据来自加拿大COVID-19急诊科快速响应网络(CCEDRRN)的10个参与站点。
- 纳入2021年7月19日至12月31日期间因COVID-19症状就诊并接受SARS-CoV-2核酸扩增检测的急诊患者。
- 排除疫苗接种情况不明确或急诊就诊时接种一剂或多于2剂疫苗的患者。
- 共纳入3405例符合条件的患者。
主要发现
- 在3405例 eligible 患者中,接种后7-55天调整两剂mRNA疫苗对SARS-CoV-2相关急诊就诊的VE为93.3%(95%CI 87.9-96.3%)。
- VE在接种后139天内维持80%以上。
- 在分层分析中,VE在患有特定免疫受损状况、慢性肾病、肺病、住房不稳定及报告非法药物使用的患者中相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: During the COVID-19 pandemic, clinical care shifted toward virtual and Emergency Department care. We explored the feasibility of mRNA vaccine effectiveness (VE) estimation against SARS-CoV-2-related Emergency Department visits and hospitalizations using prospectively collected Emergency Department data. METHODS: We estimated two-dose VE using a test-negative design and data from 10 participating sites of the Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN). We included Emergency Department patients presenting with COVID-19 symptoms and nucleic acid amplification testing for SARS-CoV-2 between July 19 and December 31, 2021. We excluded patients with unclear vaccination and one or more than 2 vaccine doses by their Emergency Department visit. RESULTS: Among 3,405 eligible patients, adjusted two-dose mRNA VE against SARS-CoV-2-related Emergency Department visits was 93.3 % (95 % CI 87.9-96.3 %) between 7-55 days, sustained over 80 % through 139 days post-vaccination. In stratified analyses, VE was similar among patients with select immune-compromising conditions, chronic kidney disease, lung disease, unstable housing, and reported illicit substance use. CONCLUSIONS: Two-dose mRNA VE against SARS-CoV-2-related Emergency Department visit was high and sustained, including among vulnerable subgroups. Compared to administrative datasets, active Emergency Department enrolment enables standardization for testing access and indication and supports separate VE assessment among special population subgroups. Compared to other active enrolment settings, Emergency Departments more consistently function during crises when alternate healthcare sectors become variably closed. TRIAL REGISTRATION: Clinicaltrials.gov, NCT0470294.
引用
- Ting DK, Rosychuk RJ, Hau JP, et al. Leveraging a clinical emergency department dataset to estimate two-dose COVID-19 vaccine effectiveness and duration of protection in Canada. Vaccine. 2024. PMID: 38879407. doi:10.1016/j.vaccine.2024.06.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。